Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
277 results about "Adrenergic receptor agonists" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Adrenergic agonist. An adrenergic agonist is a drug that stimulates a response from the adrenergic receptors. The five main categories of adrenergic receptors are: α1, α2, β1, β2, and β3, although there are more subtypes, and agonists vary in specificity between these receptors, and may be classified respectively.
Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
InactiveUS20050020600A1Effective treatmentTreatment safetyBiocidePharmaceutical delivery mechanismQuinoxalineVasomotor instability
The present invention relates to a method of treating, reducing, inhibiting, preventing and / or reversing cutaneous facial flushing caused by abnormal, endogenously-induced vasomotor instability associated with, but not limited to acne rosacea, menopause-associated hot flashes, hot flashes resulting from orchiectomy or ingestion of substances capable of inducing a cutaneous facial flushing reaction (e.g.: alcohol, chocolate, spices) by topical dermatological application of an effective dose of a composition comprising at least one α2 adrenergic receptor agonist (such as a (2-imidazolin-2-ylamino) quinoxaline derivative such as brimonidine tartrate)and a suitable carrier.
Owner:GALDERMA LAB LP
Methods and compositions for the prevention of tolerance to medications
InactiveUS6235725B1Avoid toleranceEasy to managePowder deliveryBiocideTolerabilityAdrenergic receptor agonists
The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to beta2-adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.
Owner:TEVA WOMENS HEALTH RES INC
Diamine beta2 adrenergic receptor agonists
The invention provides novel β2 adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with β2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.
Owner:THERAVANCE BIOPHARMA R&D IP LLC
Treating skin disorders
InactiveUS20070082070A1Reduce severitySolve skin problemsBiocideHydroxy compound active ingredientsAdrenergicAlpha-2 adrenergic receptor
This document relates to methods and materials involved in treating skin disorders. For example, methods and materials for using an alpha adrenergic receptor agonist (e.g., midodrine) to treat mammals having a skin disorder are provided.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES
Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
InactiveUS20070014843A1Reducing regional fat accumulationGood lookingBiocideMetabolism disorderAdrenergicAdrenergic receptor agonists
Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and / or ketotifen. Embodiments of the composition are administered, for example, by injection, and / or transdermally.
Owner:LITHERA
Pharmaceutical Compositions and Related Methods of Treatment
InactiveUS20080021074A1Decrease and prevent sleepinessDecrease and prevent and lethargyBiocideNervous disorderAdrenergic receptor agonistsClumsiness
Pharmaceutical compositions comprising at least one alpha2-adrenergic agonist or baclofen and at least one alpha1-adrenergic agonist are disclosed. Pharmaceutical compositions comprising tizanidine and modafinil are disclosed. Methods for reducing somnolence, sleepiness, lethargy, dizziness, drowsiness, somnolence, tiredness, lightheadedness, increased weakness, confusion, unsteadiness, clumsiness, or a combination of the symptoms thereof in a human patient; treating pain; and attenuating muscle spasticity, using pharmaceutical compositions comprising at least one alpha2-adrenergic agonist or baclofen and at least one alpha1-adrenergic agonist are disclosed.
Owner:QUESTCOR PHARMA
Functionally selective alpha2C adrenoreceptor agonists
InactiveUS20080027100A1Minimizing adverse side effectReduce usageBiocideSenses disorderAdrenergicAdrenergic receptor agonists
In its many embodiments, the present invention provides a novel class of indolines as inhibitors of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.
Owner:MERCK SHARP & DOHME CORP +1
Methods and compositions for modulating the mobilization of stem cells
InactiveUS20070190023A1Enhance mobilizationPrevent egressBiocidePeptide/protein ingredientsDiseaseCXCR4
Methods and compositions for modulating the mobilization of stem cells, particularly for promoting or increasing the mobilization of hematopoietic stem cells from the bone marrow to the peripheral blood are disclosed. In particular, the invention relates to the use of adrenergic agonists that act in concert with a mobilization compound or agent. The mobilization agent(s) may act to decrease the expression or function of the chemokine, CXCL12, or may act to block or antagonize CXCR4. The invention also relates to methods of using these compounds or agents for enhancing the mobilization of hematopoietic stem cells when harvesting of the stem cells is necessary for the treatment of diseases, disabilities or conditions whereby transplantation of such cells would be beneficial in ameliorating the symptoms associated with such diseases, disabilities or conditions. Methods of screening for novel agents and pharmaceutical compositions comprising these agents are also disclosed.
Owner:MT SINAI SCHOOL OF MEDICINE
Aryl aniline derivatives as beta2 adrenergic receptor agonists
The invention provides novel β2 adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with β2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.
Owner:THERAVANCE BIOPHARMA R&D IP LLC
Compositions and methods for treatment of cachexia
InactiveUS8080528B2Prevent and treat cachexiaLower Level RequirementsBiocideMetabolism disorderAdrenergicAdrenergic receptor agonists
Owner:THE RELEEF INITIATIVE
Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators
InactiveUS20060264509A1Limited efficacyReduce patient complianceBiocideOrganic active ingredientsGabapentinAdrenergic receptor agonists
A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat pain. According to the present invention, α2δ subunit calcium channel modulators include GABA analogs (e.g., gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
Owner:DYNOGEN PHARM INC
Local anesthetic methods and kits
Owner:SEPTODONT HLDG
Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
InactiveUS20100009934A1Reduce the impactBiocideHydroxy compound active ingredientsAdrenergicInhalation
The invention features a method of treating a B-cell proliferative disorder by administering to a patient a BAR agonist, e.g., formulated for administration by a route other than inhalation (such as for oral or intravenous administration), in an amount effective to treat the B-cell proliferative disorder. The BAR agonist may be administered as a monotherapy or in combination with one or more other agents, e.g., a PDE inhibitor, an A2A receptor agonist, or an antiproliferative compound, in amounts that together are effective to treat the B-cell proliferative disorder. The invention further features pharmaceutical compositions and kits including a BAR agonist, alone or in combination with additional agents, for the treatment of a B-cell proliferative disorder.
Owner:ZALICUS INC
Carbazolyl-substituted ethanolamines as selective beta -3 agonists
InactiveUS6140352AAvoid insufficient purityBiocideNervous disorderAdrenergic receptor agonistsEthanolamines
PCT No. PCT / US97 / 15230 Sec. 371 Date May 4, 1998 Sec. 102(e) Date May 4, 1998 PCT Filed Aug. 28, 1997 PCT Pub. No. WO98 / 09625 PCT Pub. Date Mar. 12, 1998Disclosed herein are selective beta 3 adrenergic agonists represented by the following structural formula: The variables in the structural formula shown above are defined in the specification. Also disclosed are methods of using these compounds for agonizing the beta 3 adrenergic receptor in patients in need of such treatment, for example, patients in need of treatment for obesity or Type II diabetes.
Owner:ELI LILLY & CO
Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators
Owner:EDUSA PHARMA
Method for treating pulmonary diseases using rho kinase inhibitor compounds
InactiveUS20100204210A1Not effectiveBiocidePharmaceutical delivery mechanismDiseaseOccupational pulmonary disease
This invention relates to methods of treating pulmonary diseases in patients that beta adrenergic receptor agonist therapy is not effective. The method comprises the steps of: identifying a patient who suffers from a pulmonary disease and has reduced responsiveness to treatment with one or more beta adrenergic receptor agonists, and administering to the patient an effective amount of a Rho kinase inhibitor compound, wherein said pulmonary disease is selected from the group consisting of: asthma, chronic obstructive pulmonary disease, respiratory tract illness caused by respiratory syncytial virus infection such as RSV-induced wheezing, airway hyperreactivity, or bronchiolitis, bronchiectasis, alpha-1-antitrypsin deficiency, lymphangioleiomyomatosis, cystic fibrosis, bronchiolitis or wheezing caused by agents other than respiratory syncytial virus, chronic bronchitis, and occupational lung diseases.
Owner:INSPIRE PHARMA
.beta.3 adrenergic agonists
InactiveUS6730792B2Reduce the possibilityBiocidePowder deliveryAdrenergic receptor agonistsEnergy expenditure
Owner:ELANCO US INC
Blocking induction of tetrahydrobioterin to block induction of nitric oxide synthesis
InactiveUS6153615AReduce inhibitionRestore sensitivityBiocidePeptide/protein ingredientsSide effectTreatment effect
Guanosine triphosphate pathway tetrahydrobiopterin synthesis antagonist and / or pterin salvage pathway tetrahydrobiopterin synthesis antagonists are administered to inhibit nitric oxide synthesis from arginine in vascular cells in a subject in need of such inhibition (e.g., for prophylactic or curative effect for endotoxin- or cytokine-induced hypotension or for restoration of vascular contractile sensitivity to pressor agents in the treatment of such hypotension). The tetrahydrobiopterin synthesis antagonist may be administered with alpha 1-adrenergic agonist or with nitric oxide synthase inhibitor. The tetrahydrobiopterin synthesis antagonists are also administered to attenuate inflammation caused by induced nitric oxide production in immune cells. Unwanted counterproductive or side effects can be eliminated or ameliorated by administration additionally of levodopa with or without carbidopa and L-5-hydroxytryptophane.
Owner:CORNELL RES FOUNDATION INC
Crystalline beta2 adrenergic receptor agonist
The invention provides a crystalline salt form of a novel β2 adrenergic receptor agonist. The invention also provides pharmaceutical compositions comprising the crystalline form, formulations containing the pharmaceutical compositions, methods of using the crystalline salt form to treat diseases associated with β2 adrenergic receptor activity, and processes useful for preparing such a crystalline compound.
Owner:THERAVANCE INC
Methods for decreasing detrusor muscle overactivity
InactiveUS20050239890A1Limited efficacyReduce patient complianceBiocideOrganic active ingredientsDiseaseGabapentin
A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and / or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, α2δ subunit calcium channel modulators include GABA analogs, e.g., gabapentin and pregabalin, fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
Owner:DYNOGEN PHARM INC
Extended release alpha-2 agonist pharmaceutical dosage forms
InactiveUS20050118256A1Sufficient effectFacilitated releaseBiocideDigestive systemAdrenergic receptor agonistsAgonist drugs
Disclosed is an extended release pharmaceutical formulation containing at least an alpha-2 adrenergic agonist, such as tizanidine, for the treatment and prevention of spasticity in a subject, e.g., painful inflammatory conditions associated with skeletal muscle spasms.
Owner:GLENMARK PHARMACEUTICALS LIMITED
Compositions and methods for reducing activation of alpha-1 receptors
The invention generally relates to compositions and methods for reducing activation of a-1 adrenergic receptors. The compositions comprise highly selective a-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
Owner:EYE THERAPIES
Compositions and methods for differentiating pluripotent stem cells into primitive blood cells and uses thereof
InactiveUS20130171110A1High expressionAccelerate self-renewalBiocideCulture processInduced pluripotent stem cellAntioxidant
Compositions and methods that employ various combinations of such factors as retinoic acid signaling inhibitors, antioxidants, BMP4, VEGF, prostaglandin E2 pathway stimulants, TPO, SCF, FLT-3, EPO, TGFβ1, p38 MAPK inhibitors, beta adrenergic receptor agonists, cell cycle inhibitors, RXR agonists, Cripto, and chromatin remodelers to drive differentiation of pluripotent stem cells towards primitive blood cells. Uses of such primitive blood cells are provided.
Owner:NUCLEUS BIOLOGICS LLC
Selective beta3 adrenergic agonists
The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective beta3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II:
Owner:ELI LILLY & CO
Methods and compositions for treating or preventing erythema
Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one α-adrenergic receptor agonist and a pharmaceutically acceptable carrier.
Owner:GALDERMA HLDG SA
Aryl aniline beta2 adrenergic receptor agonists
Owner:THERAVANCE BIOPHARMA R&D IP LLC
Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators
InactiveUS20060247311A1Need lessLimited efficacyBiocidePeptide/protein ingredientsDiseaseGabapentinoid
A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and / or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, α2δ subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
Owner:DYNOGEN PHARM INC
Drug delivery systems for stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
InactiveUS20060257388A1Increase blood flowShorten the timeBiocidePeptide/protein ingredientsAnesthetic AgentAdrenergic
The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist. The invention further relates to drug delivery systems for administering alpha adrenergic receptor antagonists.
Owner:NOVALAR PHARMA INC
Alpha2C adrenoreceptor agonists
In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as α2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the α2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.
Owner:SCHERING CORP +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com